Immunogen (IMGN) surges on 'home run' ovarian cancer treatment trial data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq leads Wall St higher as Nvidia eases AI growth concerns
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil gains as traders weigh prospects of easing Middle East supply disruptions
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- Revolution Medicines prices RASONQUE at $39,800 per month
ELAHEREĀ® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRĪ±-Positive Platinum-Resistant Ovarian Cancer
May 3, 2023 6:30 AM EDTResults Show Statistically Significant Improvements in PFS, ORR, and OS Compared to Chemotherapy
First Medicine to Demonstrate an Overall Survival Advantage in Platinum-Resistant Ovarian Cancer
Submission of MAA in Europe and sBLA in US Anticipated in H2 2023
Conference Call to be Held at 8:00 AM ET Today
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen Inc. (Nasdaq:... More
